Actively Recruiting
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
Led by University of Washington · Updated on 2026-01-15
1500
Participants Needed
1
Research Sites
1017 weeks
Total Duration
On this page
Sponsors
U
University of Washington
Lead Sponsor
N
National Cancer Institute (NCI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study collects and studies tissue and blood samples from patients with prostate or bladder/urothelial cancer that has recurred (come back) at or near the same place as the original (primary) tumor or has spread to other parts of the body. Studying samples of blood and tissue samples from patients with prostate or bladder/urothelial cancer in the laboratory may help doctors learn more about new biomarkers, potential drug targets, and resistance developing in response to treatment. It may also help doctors find better ways to treat the cancer.
CONDITIONS
Official Title
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with localized and/or metastatic bladder/urothelial or prostate cancer with disease in the primary organ, accessible bone metastases, or soft tissue metastases
- Men and women without cancer eligible for blood or normal tissue collection during non-research procedures
- Ability to understand and give informed consent
- Local or metastatic disease accessible for biopsy with minimal risk, or ability to obtain tissue from surgical procedures or archival sources
- Platelet count greater than 50,000
- White blood cell count greater than 1,500
- Hemoglobin level greater than 8.0
- International normalized ratio less than 1.5
- Partial thromboplastin time less than 45
- No history of unexplained excessive bleeding from surgery
You will not qualify if you...
- Unable to stop chronic anticoagulation with warfarin or Lovenox for less than 3 days
- Serious or uncontrolled infection
- Treatment with a vascular endothelial growth factor (VEGF) inhibitor like Avastin within the past 28 days
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, United States, 98109
Actively Recruiting
Research Team
R
Robert B. Montgomery
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here